Home » Stocks » RXDX

Prometheus Biosciences, Inc. (RXDX)

Stock Price: $16.82 USD 0.02 (0.12%)
Updated May 14, 2021 4:00 PM EDT - Market closed
After-hours: $16.50 -0.32 (-1.90%) May 14, 4:35 PM
Market Cap 140.26M
Revenue (ttm) 1.23M
Net Income (ttm) n/a
Shares Out 8.34M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $16.82
Previous Close $16.80
Change ($) 0.02
Change (%) 0.12%
Day's Open 16.76
Day's Range 16.65 - 17.69
Day's Volume 30,963
52-Week Range 16.11 - 30.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.

Other stocks mentioned: THMO, VYNT
1 week ago - Benzinga

Auris Medical Holding Ltd. (NASDAQ: EARS), CytoDyn Inc. (OTC: CYDY) and Prometheus Biosciences, Inc. (NASDAQ: RXDX) are among the biggest movers in the biopharma space Thursday.

Other stocks mentioned: CYDY, EARS
1 month ago - Benzinga

Steven Cohen ( Trades , Portfolio ) has revealed a new buy into Prometheus Biosciences Inc. (NASDAQ:RXDX) alongside an addition to his position in Curis Inc. (NASDAQ:CRIS) according to GuruFocus Real-Ti...

Other stocks mentioned: AMD, CRIS, FB, GOOGL, MSFT, V
1 month ago - GuruFocus

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders took advantage of initial public offerings in the past week.

Other stocks mentioned: CPNG, KDP, BHVN, GOCO, INVA, JOAN, MBIN ...
1 month ago - Benzinga

SAN DIEGO, March 16, 2021 /PRNewswire/ -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercializat...

1 month ago - PRNewsWire

Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development,...

2 months ago - PRNewswire

Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, filed on Friday with the SEC to raise up to $125 million in an initial public offering.

2 months ago - NASDAQ

Prometheus Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC

About RXDX

Prometheus Biosciences is a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD). We leverage our proprietary precision medicine platform, Prometheus360™, which includes one of the world’s largest gastrointestinal (GI) bioinformatics databases, to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. In parallel, we are developing ... [Read more...]

Industry
Biotechnology
IPO Date
Mar 12, 2021
CEO
Mark C. McKenna
Employees
24
Stock Exchange
NASDAQ
Ticker Symbol
RXDX
Full Company Profile

Financial Performance

In 2020, RXDX's revenue was $1.23 million, an increase of 9.93% compared to the previous year's $1.12 million. Losses were -$37.14 million, 24.9% more than in 2019.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for RXDX is 32.25, which is an increase of 91.74% from the latest price.

Price Target
$32.25
(91.74% upside)